corticobasal degeneration

corticobasal degeneration
Name	Corticobasal Degeneration
Synonyms	Corticobasal syndrome, CBD
Symptoms	Asymmetric parkinsonism, alien limb phenomenon, apraxia, dystonia
Complications	Dysphagia, pneumonia, falls
Onset	Typically 60-70 years
Duration	Progressive
Types	N/A
Causes	Unknown
Risks	Unknown
Diagnosis	Based on clinical features, supported by neuroimaging
Differential	Progressive supranuclear palsy, Alzheimer's disease, frontotemporal dementia
Prevention	None
Treatment	Supportive, symptomatic management
Medication	Levodopa, clonazepam, botulinum toxin
Prognosis	Poor; survival 6-9 years from onset
Frequency	~1 per 100,000
Deaths	From complications

corticobasal degeneration is a rare, progressive neurodegenerative disease characterized by the accumulation of abnormal tau protein in specific brain regions. It is classified as a primary tauopathy and a form of frontotemporal lobar degeneration, leading to the gradual deterioration of the cerebral cortex and the basal ganglia. The condition typically presents with strikingly asymmetric motor and cognitive deficits, creating a complex clinical picture that overlaps with other disorders like Parkinson's disease.

Signs and symptoms

The clinical presentation is marked by profound asymmetry, often beginning in one limb. Core motor features include akinetic-rigid parkinsonism poorly responsive to dopaminergic therapy, limb dystonia, and myoclonus. The alien limb phenomenon, where a limb moves involuntarily and seems foreign to the patient, is a classic but not universal sign. Cortical sensory loss and ideomotor apraxia, an inability to perform learned movements on command, are common. Cognitive and behavioral symptoms often align with frontotemporal dementia, including executive dysfunction, aphasia, and behavioral disinhibition. Oculomotor abnormalities, such as impaired saccadic eye movements, and dysarthria are also frequently observed.

Causes and pathophysiology

The exact cause remains unknown, with no clear genetic or environmental risk factors identified in most cases. The fundamental pathophysiology involves the abnormal aggregation of hyperphosphorylated tau protein into neuronal and glial inclusions, specifically astrocytic plaques and thread-like lesions in both gray and white matter. This pathology leads to severe neuronal loss and gliosis, predominantly affecting the frontal and parietal cortices, the substantia nigra, and the striatum. The disease is sporadic, though rare familial cases have been reported, and it shares pathological features with other tauopathies like Progressive supranuclear palsy.

Diagnosis

Diagnosis is primarily clinical, based on established criteria such as those from the International Parkinson and Movement Disorder Society. Key supportive features include the presence of progressive, asymmetric corticobasal syndrome. Neuroimaging plays a crucial supportive role; magnetic resonance imaging often reveals asymmetric frontoparietal atrophy and corpus callosum thinning, while positron emission tomography with fluorodeoxyglucose shows corresponding asymmetric hypometabolism. DaTscan imaging may show reduced dopamine transporter uptake, but this does not distinguish it from other parkinsonian syndromes. Definitive diagnosis requires neuropathological examination at autopsy.

Treatment and management

There is no disease-modifying therapy; management is entirely supportive and symptomatic. A trial of levodopa is often attempted for parkinsonism, but responses are typically minimal and transient. Clonazepam may be used for myoclonus, and botulinum toxin injections can help manage focal dystonia and drooling. Physical therapy and occupational therapy are essential for maintaining mobility and function, while speech-language pathology can assist with dysphagia and communication difficulties. Multidisciplinary care involving neurology, palliative care, and social services is critical as the disease advances.

Prognosis

The prognosis is poor, with the disease following an inexorably progressive course. Median survival from symptom onset is approximately 6 to 9 years. The terminal stages are characterized by severe global akinesia, mutism, and dysphagia, leading to complications such as aspiration pneumonia, which is a common cause of death. The rate of progression and the specific constellation of disabling symptoms can vary significantly between individuals, but all lead to a state of profound physical and cognitive disability.

Epidemiology

Corticobasal degeneration is considered a very rare disorder, with an estimated prevalence of roughly 1 case per 100,000 individuals. The mean age of onset is typically in the seventh decade, around 60 to 70 years, though onset can occur earlier or later. There is no consistent evidence for a gender predilection, affecting men and women equally. Due to its clinical overlap with other conditions like Alzheimer's disease and dementia with Lewy bodies, it is likely underdiagnosed in life, with true prevalence figures best established through epidemiological neuropathology studies.

Category:Neurodegenerative disorders Category:Movement disorders Category:Tauopathies